The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study

Domiziana Rinaldi, Edoardo Bianchini, Michela Sforza, Marika Alborghetti, Silvia Galli, Marco Salvetti, Morena Giovannelli, Francesco E Pontieri

Research output: Contribution to journalArticlepeer-review

Abstract

Safinamide (SF) is a third-generation monoamine-oxidase-B inhibitor that proved efficacy as add-on to levodopa in fluctuating Parkinson's disease (PD) patients. Despite the high prevalence of complicated PD in older population, the data on the tolerability, safety and efficacy of SF in elderly patients are rather poor. Here we studied retrospectively the consequences of add-on with SF in PD patients older than 65 years. Fifty-three fluctuating PD patients were included (30 subjects aged between 65 and 75 years, the remaining 23 subjects aged > 75 years). Patients were treated with either 50 (n = 27) or 100 mg (n = 26) SF for at least 6 months. In all patients, fluctuations were identified by the report of a Wearing-Off-Questionnaire-19 (WOQ-19) score ≥ 3 at baseline. Add-on with SF was well tolerated and safe. Adverse events occurred in 30% of patients and led to drug discontinuation in 11% of cases. At follow-up visits, 60% of patients reported lowering of the WOQ-19 score to ≤ 2. There were no significant differences related to age or daily drug dose in tolerability, safety or efficacy. The results of this study provide evidence of the efficacy, tolerability and safety of SF in elderly PD patients.

Original languageEnglish
JournalAging Clin. Exp. Res.
DOIs
Publication statusE-pub ahead of print - Jul 17 2020

Fingerprint Dive into the research topics of 'The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study'. Together they form a unique fingerprint.

Cite this